Allergan Hunts for Small Acquisitions
Source: Bloomberg
Jul 01, 2016
Allergan CEO says the company is hunting for smaller acquisitions to boost growth after its $160 billion Pfizer merger fell through.
CEO Brent Saunders said in a Bloomberg tv interview, "With respect to M&A, we will be looking at more smaller-scale tuck-in deals that will support our therapeutic area leadership and innovation."
Allergan will have $20 billion to invest in growth and innovation after it sells its generic business to Teva.
Read the Bloomberg release
Show Comments
Join the discussion
We welcome your thoughtful comments.
All comments will display your user name.
Comments
No one has commented on this page yet.
RSS feed for comments on this page | RSS feed for all comments